Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6411008 | 1.00 | ELANE (0.33) | ELANE | |
| SCHEMBL3396875 | 1.00 | ELANE (0.33) | ELANE | |
| SCHEMBL27340948 | 0.98 | ELANE (0.32) | ELANE | |
| SCHEMBL9384822 | 0.84 | — | — | |
| SCHEMBL9384813 | 0.84 | — | — | |
| SCHEMBL11474634 | 0.84 | — | — | |
| SCHEMBL10761000 | 0.82 | ELANE (0.32) | ELANE | |
| Potassium Ion SCHEMBL11390304 | 0.82 | — | — | |
| SCHEMBL10760996 | 0.82 | ELANE (0.32) | ELANE | |
| SCHEMBL10771180 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0666862-A1 | 6-(SUBSTITUTED METHYLENE) PENEMS AND INTERMEDIATES | SMITHKLINE BEECHAM PLC (GB) | 1995-08-16 | — | — | EP | claimed |
| WO-1994003168-A1 | 5 S PENEM DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM PLC (GB) | 1994-02-17 | — | — | WO | claimed |
| CN-1021735-C | Process for producing carbapenem compound | ERBA FARMITALIA (IT) | 1993-08-04 | — | — | CN | claimed |
| EP-0443883-A1 | Carbapenem derivatives having antibiotic activity, their preparation and their use | Sankyo Company Limited (JP) | 1991-08-28 | — | — | EP | claimed |
| US-4692442-A | ANTIBIOTICS | CIBA-GEIGY CORPORATION (US) | 1987-09-08 | — | — | US | claimed |
| EP-0201206-A1 | Penem derivatives | FARMITALIA CARLO ERBA S.r.l. (IT) | 1986-11-12 | — | — | EP | claimed |
| EP-0167100-A1 | Penem derivatives | FARMITALIA CARLO ERBA S.r.l. (IT) | 1986-01-08 | — | — | EP | claimed |
| US-4500457-A | TREATING AN ACYLOXYAZETIDINONE WITH MERCAPTO COMPOUND, GLYOYLIC ESTER, HALOGENATION AGENT, AND PHOSPHINE COMPOUNT THEN CYCLIZATION | CIBA-GEIGY CORPORATION (US) | 1985-02-19 | — | — | US | claimed |
| EP-0003960-B1 | 6-SUBSTITUTED THIA-AZA-COMPOUNDS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CIBA-GEIGY AG (CH) | 1983-06-29 | — | — | EP | claimed |
| US-4331676-A | 2-PENEM COMPOUNDS UNSUBSTITUTED IN THE 6 POSITION | CIBA-GEIGY CORPORATION (US) | 1982-05-25 | — | — | US | claimed |
| JP-57009784-A | — | — | None | — | — | JP | disclosed |
| US-20100261700-A1 | BETA-LACTAMASE INHIBITORS | SOPHARMIA, INC. | 2010-10-14 | — | — | US | disclosed |
| WO-2010118361-A1 | BETA LACTAMASE INHIBITORS | SOPHARMIA, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| CN-101842096-A | Film-coated preparation | DAIICHI SANKYO CO LTD | 2010-09-22 | — | — | CN | disclosed |
| EP-1870412-A1 | 2-THIOETHENYL CARBAPENEM DERIVATIVE | MEIJI SEIKA KAISHA LTD. (JP) | 2007-12-26 | — | — | EP | disclosed |
| US-4192801-A | Novel phosphorane intermediates for use in preparing penem antibiotics | BRISTOL-MYERS COMPANY (US) | 1980-03-11 | — | — | US | disclosed |
| US-4182711-A | 2-PHENEM-3-CARBOXYLATE ANTIBIOTICS | BRISTOL-MYERS COMPANY (US) | 1980-01-08 | — | — | US | disclosed |
| US-4169833-A | NOVEL PHOSPHORANE INTERMEDIATES FOR USE IN PREPARING PENEM ANTIBIOTICS | BRISTOL-MYERS COMPANY (US) | 1979-10-02 | — | — | US | disclosed |
| EP-0002210-A1 | 6- and 6,6- disubstituted-2-substituted-pen-2-em-3-carboxylic acids; processes for their preparation and pharmaceutical compositions containing such compounds | MERCK & CO. INC. (US) | 1979-06-13 | — | — | EP | disclosed |
| US-4155912-A | 2-Methylpenem-3-carboxylic acid antibiotics | BRISTOL-MYERS COMPANY (US) | 1979-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261700-A1 | BETA-LACTAMASE INHIBITORS | PEPD, LCT, GAA | ELANE 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.